| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polyamines | 56 | 2022 | 79 | 5.520 |
Why?
|
| Histone Demethylases | 14 | 2022 | 22 | 4.300 |
Why?
|
| Spermine | 23 | 2022 | 49 | 2.610 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 20 | 2022 | 39 | 2.300 |
Why?
|
| Antineoplastic Agents | 27 | 2022 | 1070 | 2.260 |
Why?
|
| Enzyme Inhibitors | 17 | 2018 | 659 | 1.670 |
Why?
|
| Histone Deacetylase Inhibitors | 7 | 2014 | 116 | 1.220 |
Why?
|
| Antimalarials | 6 | 2022 | 71 | 1.030 |
Why?
|
| Thiourea | 4 | 2015 | 16 | 1.020 |
Why?
|
| Neuroblastoma | 2 | 2022 | 109 | 0.960 |
Why?
|
| Acetyltransferases | 20 | 2018 | 49 | 0.950 |
Why?
|
| Epigenesis, Genetic | 7 | 2016 | 163 | 0.910 |
Why?
|
| Structure-Activity Relationship | 18 | 2015 | 420 | 0.900 |
Why?
|
| Spermidine | 10 | 2022 | 21 | 0.720 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2022 | 6 | 0.690 |
Why?
|
| Drug Discovery | 3 | 2022 | 94 | 0.630 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2018 | 204 | 0.630 |
Why?
|
| Cell Line, Tumor | 19 | 2022 | 1851 | 0.630 |
Why?
|
| Biogenic Polyamines | 5 | 2009 | 8 | 0.620 |
Why?
|
| Periodontitis | 1 | 2018 | 47 | 0.610 |
Why?
|
| Alanine | 1 | 2018 | 38 | 0.610 |
Why?
|
| Animals | 49 | 2022 | 20881 | 0.610 |
Why?
|
| Adenosylmethionine Decarboxylase | 8 | 2018 | 8 | 0.610 |
Why?
|
| Peptides, Cyclic | 1 | 2018 | 35 | 0.600 |
Why?
|
| Transferases | 4 | 2013 | 14 | 0.580 |
Why?
|
| Urea | 3 | 2015 | 51 | 0.580 |
Why?
|
| Drug Design | 3 | 2013 | 107 | 0.570 |
Why?
|
| Osteogenesis | 1 | 2018 | 152 | 0.570 |
Why?
|
| Humans | 92 | 2022 | 68618 | 0.550 |
Why?
|
| Hydroxamic Acids | 2 | 2008 | 84 | 0.550 |
Why?
|
| Diamines | 1 | 2016 | 9 | 0.540 |
Why?
|
| Cytokines | 3 | 2021 | 866 | 0.520 |
Why?
|
| Deoxyadenosines | 5 | 1995 | 5 | 0.500 |
Why?
|
| Pyridines | 3 | 2013 | 261 | 0.500 |
Why?
|
| Cell Membrane | 2 | 2016 | 525 | 0.480 |
Why?
|
| Cyclopentanes | 4 | 1995 | 15 | 0.480 |
Why?
|
| Carbon | 1 | 2015 | 122 | 0.460 |
Why?
|
| Epigenomics | 1 | 2013 | 29 | 0.450 |
Why?
|
| Plasmodium falciparum | 5 | 2022 | 45 | 0.450 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2009 | 35 | 0.440 |
Why?
|
| Oximes | 1 | 2012 | 10 | 0.430 |
Why?
|
| Benzamides | 3 | 2019 | 156 | 0.430 |
Why?
|
| Isoenzymes | 3 | 2011 | 308 | 0.420 |
Why?
|
| Tumor Cells, Cultured | 21 | 2013 | 852 | 0.410 |
Why?
|
| Encephalitozoon cuniculi | 3 | 2009 | 3 | 0.410 |
Why?
|
| Hydrogen Peroxide | 6 | 2022 | 168 | 0.410 |
Why?
|
| Guanidines | 3 | 2013 | 32 | 0.400 |
Why?
|
| Biochemistry | 1 | 2011 | 12 | 0.380 |
Why?
|
| Antiprotozoal Agents | 3 | 2006 | 23 | 0.380 |
Why?
|
| DNA Damage | 7 | 2020 | 190 | 0.370 |
Why?
|
| Ornithine Decarboxylase | 7 | 2021 | 17 | 0.360 |
Why?
|
| Benzene Derivatives | 1 | 2010 | 12 | 0.360 |
Why?
|
| Protozoan Proteins | 1 | 2010 | 25 | 0.360 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2010 | 47 | 0.360 |
Why?
|
| Societies, Scientific | 1 | 2009 | 18 | 0.350 |
Why?
|
| Gene Expression Regulation, Enzymologic | 6 | 2010 | 282 | 0.350 |
Why?
|
| Dipeptides | 1 | 2010 | 89 | 0.350 |
Why?
|
| Eflornithine | 4 | 2021 | 15 | 0.340 |
Why?
|
| Malaria, Falciparum | 2 | 2022 | 10 | 0.340 |
Why?
|
| HIV Protease | 3 | 2013 | 7 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.330 |
Why?
|
| HIV Protease Inhibitors | 3 | 2013 | 25 | 0.330 |
Why?
|
| Cell Survival | 8 | 2018 | 901 | 0.320 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 475 | 0.320 |
Why?
|
| Putrescine | 9 | 2013 | 17 | 0.310 |
Why?
|
| Oxidoreductases, N-Demethylating | 3 | 2009 | 3 | 0.300 |
Why?
|
| Molecular Structure | 9 | 2013 | 397 | 0.300 |
Why?
|
| Lung Neoplasms | 10 | 2013 | 1173 | 0.300 |
Why?
|
| Mice | 22 | 2022 | 8474 | 0.300 |
Why?
|
| Helicobacter Infections | 2 | 2020 | 40 | 0.290 |
Why?
|
| Stomach Neoplasms | 2 | 2020 | 64 | 0.290 |
Why?
|
| Oxidative Stress | 5 | 2019 | 718 | 0.290 |
Why?
|
| Helicobacter pylori | 2 | 2020 | 54 | 0.290 |
Why?
|
| Furocoumarins | 4 | 2004 | 9 | 0.280 |
Why?
|
| Citrus | 4 | 2004 | 12 | 0.280 |
Why?
|
| Gene Silencing | 4 | 2013 | 137 | 0.280 |
Why?
|
| Trypanosoma brucei brucei | 2 | 2006 | 20 | 0.280 |
Why?
|
| Antiparasitic Agents | 2 | 2009 | 12 | 0.280 |
Why?
|
| Breast Neoplasms | 9 | 2011 | 1536 | 0.280 |
Why?
|
| Reactive Oxygen Species | 10 | 2013 | 499 | 0.270 |
Why?
|
| Sulfamethoxazole | 6 | 2005 | 15 | 0.270 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 6 | 0.260 |
Why?
|
| Dapsone | 6 | 2005 | 21 | 0.250 |
Why?
|
| Apoptosis | 14 | 2012 | 1641 | 0.250 |
Why?
|
| Chelating Agents | 1 | 2005 | 47 | 0.250 |
Why?
|
| Trypanocidal Agents | 3 | 2007 | 11 | 0.250 |
Why?
|
| Keratinocytes | 4 | 2008 | 68 | 0.250 |
Why?
|
| Copper | 3 | 2005 | 149 | 0.240 |
Why?
|
| Cells, Cultured | 7 | 2018 | 2673 | 0.240 |
Why?
|
| Magnetic Resonance Spectroscopy | 6 | 2009 | 346 | 0.240 |
Why?
|
| Escherichia coli | 7 | 2016 | 368 | 0.230 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2013 | 111 | 0.230 |
Why?
|
| Neoplasms | 5 | 2021 | 1667 | 0.230 |
Why?
|
| Models, Molecular | 5 | 2013 | 546 | 0.230 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 3 | 1999 | 12 | 0.220 |
Why?
|
| Biguanides | 2 | 2021 | 4 | 0.220 |
Why?
|
| Folic Acid Antagonists | 1 | 2022 | 20 | 0.210 |
Why?
|
| Flavins | 1 | 2022 | 5 | 0.210 |
Why?
|
| Acrolein | 1 | 2022 | 9 | 0.210 |
Why?
|
| Insulin-Secreting Cells | 2 | 2015 | 41 | 0.210 |
Why?
|
| Benzoates | 1 | 2022 | 20 | 0.210 |
Why?
|
| Recombinant Proteins | 6 | 2011 | 742 | 0.210 |
Why?
|
| Tubulin | 2 | 2001 | 60 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 2791 | 0.210 |
Why?
|
| Cell Line | 7 | 2018 | 1752 | 0.200 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 137 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2003 | 300 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 756 | 0.200 |
Why?
|
| NAD | 1 | 2022 | 73 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 116 | 0.190 |
Why?
|
| Immunologic Factors | 1 | 2021 | 87 | 0.190 |
Why?
|
| Biosynthetic Pathways | 2 | 2018 | 15 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 87 | 0.190 |
Why?
|
| Kinetics | 7 | 2010 | 1047 | 0.190 |
Why?
|
| Drug Synergism | 6 | 2021 | 260 | 0.180 |
Why?
|
| Gastritis | 1 | 2020 | 12 | 0.180 |
Why?
|
| Stereoisomerism | 4 | 2010 | 169 | 0.180 |
Why?
|
| Lysine | 3 | 2015 | 96 | 0.170 |
Why?
|
| Cell Proliferation | 6 | 2018 | 1174 | 0.170 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 299 | 0.170 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2019 | 21 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2013 | 231 | 0.170 |
Why?
|
| Bile Ducts | 1 | 2019 | 59 | 0.170 |
Why?
|
| Histone Deacetylases | 3 | 2011 | 99 | 0.170 |
Why?
|
| Necrosis | 1 | 2019 | 239 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 511 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2013 | 1745 | 0.160 |
Why?
|
| DNA | 3 | 2009 | 597 | 0.160 |
Why?
|
| Hydroxylamine | 4 | 2005 | 9 | 0.160 |
Why?
|
| Curcumin | 1 | 2018 | 23 | 0.160 |
Why?
|
| Acetylation | 2 | 2011 | 94 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 40 | 0.160 |
Why?
|
| K562 Cells | 1 | 2018 | 44 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 334 | 0.150 |
Why?
|
| HEK293 Cells | 2 | 2016 | 326 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2016 | 289 | 0.150 |
Why?
|
| Methylation | 3 | 2015 | 56 | 0.150 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 455 | 0.150 |
Why?
|
| Caenorhabditis elegans | 2 | 2016 | 38 | 0.150 |
Why?
|
| Beverages | 2 | 1999 | 50 | 0.150 |
Why?
|
| Osteoclasts | 1 | 2018 | 132 | 0.150 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 1996 | 11 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2019 | 73 | 0.140 |
Why?
|
| Erythrocytes | 3 | 2010 | 137 | 0.140 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 375 | 0.140 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2016 | 7 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 301 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 59 | 0.130 |
Why?
|
| RNA, Messenger | 7 | 2020 | 1664 | 0.130 |
Why?
|
| Biofilms | 1 | 2016 | 72 | 0.130 |
Why?
|
| Ethanol | 1 | 2022 | 893 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2016 | 226 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 133 | 0.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 92 | 0.130 |
Why?
|
| Cell Division | 10 | 2002 | 541 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2016 | 175 | 0.120 |
Why?
|
| Transfection | 4 | 2010 | 782 | 0.120 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 33 | 0.120 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 80 | 0.120 |
Why?
|
| Enzyme Induction | 6 | 2014 | 119 | 0.120 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 136 | 0.120 |
Why?
|
| Macrophages | 1 | 2018 | 647 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 157 | 0.120 |
Why?
|
| Chromatin | 2 | 2011 | 76 | 0.120 |
Why?
|
| Lopinavir | 1 | 2013 | 18 | 0.110 |
Why?
|
| Histones | 2 | 2013 | 111 | 0.110 |
Why?
|
| Molecular Weight | 2 | 2012 | 358 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2015 | 237 | 0.110 |
Why?
|
| Spectrophotometry, Infrared | 2 | 2008 | 25 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 1293 | 0.110 |
Why?
|
| Transcription, Genetic | 4 | 2015 | 562 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2013 | 8 | 0.110 |
Why?
|
| GATA4 Transcription Factor | 2 | 2010 | 33 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2013 | 62 | 0.110 |
Why?
|
| Spermine Synthase | 2 | 1989 | 12 | 0.110 |
Why?
|
| Biological Transport | 3 | 2016 | 210 | 0.110 |
Why?
|
| Cadherins | 1 | 2013 | 93 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2010 | 617 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2012 | 4 | 0.100 |
Why?
|
| Rabbits | 3 | 2009 | 509 | 0.100 |
Why?
|
| Aspartic Acid Proteases | 1 | 2012 | 4 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2013 | 954 | 0.100 |
Why?
|
| Palladium | 1 | 2011 | 12 | 0.100 |
Why?
|
| HIV-1 | 1 | 2013 | 177 | 0.100 |
Why?
|
| Campylobacter jejuni | 1 | 2011 | 2 | 0.100 |
Why?
|
| Platinum | 1 | 2011 | 17 | 0.100 |
Why?
|
| CHO Cells | 2 | 2010 | 161 | 0.100 |
Why?
|
| Adenosine | 2 | 1989 | 165 | 0.100 |
Why?
|
| Cricetinae | 2 | 2010 | 262 | 0.100 |
Why?
|
| Alkylation | 2 | 2015 | 26 | 0.100 |
Why?
|
| Models, Chemical | 2 | 2009 | 155 | 0.100 |
Why?
|
| Binding Sites | 5 | 2003 | 631 | 0.100 |
Why?
|
| Tretinoin | 1 | 2012 | 92 | 0.100 |
Why?
|
| Bacteroides fragilis | 1 | 2011 | 20 | 0.100 |
Why?
|
| Rats | 5 | 2011 | 5300 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2012 | 152 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 63 | 0.100 |
Why?
|
| Annexins | 1 | 2011 | 3 | 0.100 |
Why?
|
| Enzyme Assays | 1 | 2011 | 5 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 74 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 196 | 0.090 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 2550 | 0.090 |
Why?
|
| Cathepsin D | 1 | 2010 | 13 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 122 | 0.090 |
Why?
|
| Homeostasis | 2 | 2009 | 291 | 0.090 |
Why?
|
| HIV Infections | 2 | 2013 | 791 | 0.090 |
Why?
|
| Base Sequence | 5 | 2011 | 1015 | 0.090 |
Why?
|
| Cricetulus | 1 | 2010 | 98 | 0.090 |
Why?
|
| DNA Methylation | 4 | 2014 | 193 | 0.090 |
Why?
|
| Awards and Prizes | 1 | 2009 | 27 | 0.090 |
Why?
|
| History, 19th Century | 1 | 2009 | 95 | 0.090 |
Why?
|
| Androgens | 1 | 2009 | 41 | 0.090 |
Why?
|
| Models, Biological | 3 | 2009 | 981 | 0.090 |
Why?
|
| Internationality | 1 | 2009 | 74 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2009 | 42 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 710 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 248 | 0.080 |
Why?
|
| Metals | 1 | 2009 | 100 | 0.080 |
Why?
|
| Demography | 1 | 2009 | 279 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2009 | 246 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2009 | 87 | 0.080 |
Why?
|
| Fetus | 1 | 2009 | 157 | 0.080 |
Why?
|
| Drug Hypersensitivity | 2 | 1999 | 35 | 0.080 |
Why?
|
| Mixed Function Oxygenases | 2 | 1999 | 35 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2011 | 381 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 447 | 0.080 |
Why?
|
| Protein Binding | 5 | 2015 | 1027 | 0.080 |
Why?
|
| RNA, Small Interfering | 4 | 2012 | 434 | 0.080 |
Why?
|
| Protein Conformation | 3 | 2013 | 362 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1034 | 0.070 |
Why?
|
| Proteins | 1 | 2011 | 474 | 0.070 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 1447 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 649 | 0.070 |
Why?
|
| Methemoglobin | 2 | 1999 | 7 | 0.070 |
Why?
|
| Food-Drug Interactions | 2 | 2004 | 4 | 0.070 |
Why?
|
| Yersinia pestis | 1 | 2007 | 6 | 0.070 |
Why?
|
| Protein Biosynthesis | 2 | 2005 | 181 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 194 | 0.070 |
Why?
|
| Internet | 1 | 2009 | 390 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 179 | 0.070 |
Why?
|
| Glutathione Reductase | 1 | 2006 | 17 | 0.070 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2006 | 19 | 0.070 |
Why?
|
| Carnitine | 1 | 1986 | 17 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 1999 | 307 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 230 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2013 | 294 | 0.070 |
Why?
|
| Time Factors | 8 | 2012 | 4655 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2005 | 86 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2020 | 1692 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2009 | 902 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 97 | 0.060 |
Why?
|
| DNA Primers | 3 | 2011 | 302 | 0.060 |
Why?
|
| Felodipine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Gene Expression Profiling | 3 | 2013 | 498 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2009 | 778 | 0.060 |
Why?
|
| RNA Stability | 1 | 2005 | 55 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2005 | 241 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 138 | 0.060 |
Why?
|
| Coronary Disease | 1 | 1986 | 358 | 0.060 |
Why?
|
| Hydroxylamines | 2 | 2005 | 20 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 700 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2020 | 2689 | 0.060 |
Why?
|
| Onchocerca volvulus | 1 | 2003 | 3 | 0.060 |
Why?
|
| Cell Death | 3 | 2005 | 329 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1033 | 0.060 |
Why?
|
| Inactivation, Metabolic | 2 | 2000 | 28 | 0.060 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 2 | 2013 | 7 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 170 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2015 | 1083 | 0.060 |
Why?
|
| Cytochrome P-450 CYP3A | 3 | 1999 | 22 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 53 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 468 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 626 | 0.050 |
Why?
|
| Benzoic Acid | 1 | 2022 | 5 | 0.050 |
Why?
|
| Antimetabolites | 1 | 2002 | 17 | 0.050 |
Why?
|
| Anti-Infective Agents | 2 | 2005 | 166 | 0.050 |
Why?
|
| Female | 12 | 2021 | 38074 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 791 | 0.050 |
Why?
|
| Substrate Specificity | 4 | 2004 | 234 | 0.050 |
Why?
|
| Acetaldehyde | 1 | 2022 | 18 | 0.050 |
Why?
|
| Disulfiram | 1 | 2022 | 22 | 0.050 |
Why?
|
| HL-60 Cells | 3 | 2013 | 50 | 0.050 |
Why?
|
| Caspases | 2 | 2002 | 194 | 0.050 |
Why?
|
| Voltage-Dependent Anion Channels | 1 | 2022 | 40 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2012 | 489 | 0.050 |
Why?
|
| Leukemia | 1 | 2002 | 117 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 78 | 0.050 |
Why?
|
| DNA Fragmentation | 5 | 2000 | 85 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1174 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 84 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 89 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2022 | 122 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 94 | 0.050 |
Why?
|
| Vinblastine | 1 | 2001 | 40 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2000 | 312 | 0.050 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2013 | 14 | 0.050 |
Why?
|
| Opportunistic Infections | 1 | 2001 | 33 | 0.050 |
Why?
|
| Intestinal Mucosa | 2 | 1999 | 219 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2022 | 127 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 314 | 0.050 |
Why?
|
| Porins | 1 | 2000 | 3 | 0.050 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.040 |
Why?
|
| Autophagy | 1 | 2022 | 208 | 0.040 |
Why?
|
| beta Catenin | 1 | 2020 | 73 | 0.040 |
Why?
|
| Mitochondria | 2 | 2022 | 643 | 0.040 |
Why?
|
| Ligation | 1 | 2019 | 83 | 0.040 |
Why?
|
| Benzodioxoles | 1 | 2019 | 30 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 87 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 266 | 0.040 |
Why?
|
| Mass Spectrometry | 2 | 1998 | 284 | 0.040 |
Why?
|
| Plasmodium yoelii | 1 | 2019 | 2 | 0.040 |
Why?
|
| Parasite Load | 1 | 2019 | 2 | 0.040 |
Why?
|
| Parasitemia | 1 | 2019 | 5 | 0.040 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2019 | 8 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 200 | 0.040 |
Why?
|
| Biopolymers | 1 | 1999 | 21 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1998 | 765 | 0.040 |
Why?
|
| Malaria | 1 | 2019 | 26 | 0.040 |
Why?
|
| Monoamine Oxidase | 1 | 2018 | 26 | 0.040 |
Why?
|
| Antioxidants | 2 | 1998 | 304 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 235 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 615 | 0.040 |
Why?
|
| Cyclosporine | 1 | 1999 | 121 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 532 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2015 | 254 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 39 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 245 | 0.040 |
Why?
|
| DNA, Neoplasm | 4 | 2000 | 95 | 0.040 |
Why?
|
| Blotting, Northern | 2 | 2011 | 189 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1998 | 112 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 174 | 0.040 |
Why?
|
| Half-Life | 2 | 2009 | 96 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2013 | 332 | 0.040 |
Why?
|
| United States | 1 | 2009 | 7367 | 0.040 |
Why?
|
| Methylene Chloride | 1 | 1996 | 3 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 1 | 1996 | 52 | 0.040 |
Why?
|
| Microsomes, Liver | 1 | 1996 | 44 | 0.040 |
Why?
|
| Male | 9 | 2014 | 37321 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2012 | 190 | 0.040 |
Why?
|
| RNA | 2 | 2009 | 171 | 0.040 |
Why?
|
| RNA Interference | 2 | 2009 | 266 | 0.030 |
Why?
|
| Affinity Labels | 1 | 1995 | 66 | 0.030 |
Why?
|
| Fluorouracil | 2 | 2009 | 130 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2009 | 140 | 0.030 |
Why?
|
| Life Cycle Stages | 1 | 2015 | 7 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 514 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 65 | 0.030 |
Why?
|
| Histone Acetyltransferases | 1 | 2014 | 13 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 1995 | 128 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 1994 | 20 | 0.030 |
Why?
|
| Colombia | 1 | 2014 | 8 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1996 | 2083 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 139 | 0.030 |
Why?
|
| Glutathione | 2 | 2007 | 343 | 0.030 |
Why?
|
| Gerbillinae | 1 | 2014 | 156 | 0.030 |
Why?
|
| Liver | 1 | 2019 | 1118 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2013 | 14 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1993 | 27 | 0.030 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2013 | 67 | 0.030 |
Why?
|
| Metabolism | 1 | 2013 | 12 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 2013 | 56 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 65 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2013 | 37 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2013 | 63 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 52 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 61 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 2005 | 567 | 0.030 |
Why?
|
| Ligands | 1 | 2013 | 317 | 0.030 |
Why?
|
| Pepstatins | 1 | 2012 | 3 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 118 | 0.030 |
Why?
|
| Tranylcypromine | 1 | 2012 | 8 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 219 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 2012 | 39 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 216 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2012 | 47 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2011 | 1 | 0.030 |
Why?
|
| Transplants | 1 | 2012 | 28 | 0.030 |
Why?
|
| Carboxy-Lyases | 1 | 2011 | 5 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2012 | 75 | 0.030 |
Why?
|
| Spermidine Synthase | 1 | 2011 | 3 | 0.030 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2011 | 38 | 0.020 |
Why?
|
| DNA, Protozoan | 1 | 2011 | 8 | 0.020 |
Why?
|
| Chloroquine | 1 | 2011 | 21 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 138 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2011 | 72 | 0.020 |
Why?
|
| Biological Availability | 2 | 2004 | 79 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 320 | 0.020 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 260 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 238 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2011 | 50 | 0.020 |
Why?
|
| Etoposide | 2 | 2002 | 64 | 0.020 |
Why?
|
| Adult | 6 | 2014 | 21403 | 0.020 |
Why?
|
| Intestines | 1 | 2011 | 114 | 0.020 |
Why?
|
| Cell Separation | 2 | 2002 | 132 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 223 | 0.020 |
Why?
|
| DNA Replication | 1 | 2011 | 167 | 0.020 |
Why?
|
| Site-Specific DNA-Methyltransferase (Adenine-Specific) | 1 | 2009 | 1 | 0.020 |
Why?
|
| Colitis | 1 | 2011 | 156 | 0.020 |
Why?
|
| CpG Islands | 1 | 2009 | 51 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2009 | 57 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1989 | 62 | 0.020 |
Why?
|
| Chemistry | 1 | 1989 | 45 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 231 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 88 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 431 | 0.020 |
Why?
|
| Amines | 1 | 2009 | 98 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 114 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 492 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 304 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 280 | 0.020 |
Why?
|
| Prostate | 1 | 1989 | 116 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2008 | 12 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 1999 | 62 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 376 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 1999 | 15 | 0.020 |
Why?
|
| Middle Aged | 3 | 2014 | 21147 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 61 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 160 | 0.020 |
Why?
|
| Carnitine Acyltransferases | 1 | 1986 | 2 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 146 | 0.020 |
Why?
|
| Mitochondria, Heart | 1 | 1986 | 53 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 1038 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2005 | 66 | 0.020 |
Why?
|
| Peroxisomes | 1 | 2005 | 48 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2005 | 31 | 0.020 |
Why?
|
| Epidermis | 1 | 2005 | 42 | 0.020 |
Why?
|
| Thiazoles | 1 | 2005 | 95 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 1030 | 0.020 |
Why?
|
| Capsules | 1 | 2004 | 18 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2004 | 79 | 0.020 |
Why?
|
| Biotransformation | 1 | 2004 | 69 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 120 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 5731 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 238 | 0.010 |
Why?
|
| Enzyme Activators | 1 | 2003 | 14 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 12 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 351 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 561 | 0.010 |
Why?
|
| Microsporida | 1 | 2001 | 2 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 236 | 0.010 |
Why?
|
| Genes | 1 | 2001 | 86 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4848 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 251 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 357 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2001 | 208 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2000 | 16 | 0.010 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2000 | 12 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2000 | 19 | 0.010 |
Why?
|
| Hydrocarbons | 1 | 2000 | 12 | 0.010 |
Why?
|
| Methane | 1 | 2000 | 16 | 0.010 |
Why?
|
| Quinolinium Compounds | 1 | 1999 | 3 | 0.010 |
Why?
|
| Propylamines | 1 | 2000 | 22 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 2000 | 87 | 0.010 |
Why?
|
| Benzoxazoles | 1 | 1999 | 12 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2000 | 137 | 0.010 |
Why?
|
| Static Electricity | 1 | 2000 | 91 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2001 | 231 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 88 | 0.010 |
Why?
|
| Liposomes | 1 | 2000 | 107 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 26 | 0.010 |
Why?
|
| Cyclic N-Oxides | 1 | 1998 | 17 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1998 | 28 | 0.010 |
Why?
|
| Monocytes | 1 | 1999 | 210 | 0.010 |
Why?
|
| Hydroxyl Radical | 1 | 1998 | 17 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 1998 | 22 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1998 | 39 | 0.010 |
Why?
|
| Azides | 1 | 1998 | 56 | 0.010 |
Why?
|
| G2 Phase | 1 | 1998 | 26 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 191 | 0.010 |
Why?
|
| Bacteriophage phi X 174 | 1 | 1998 | 2 | 0.010 |
Why?
|
| Mitosis | 1 | 1998 | 76 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1998 | 200 | 0.010 |
Why?
|
| Microsomes | 1 | 1997 | 31 | 0.010 |
Why?
|
| Caco-2 Cells | 1 | 1997 | 37 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 579 | 0.010 |
Why?
|
| Estrogens | 1 | 1999 | 173 | 0.010 |
Why?
|
| Caspase 3 | 1 | 1998 | 233 | 0.010 |
Why?
|
| Plasmids | 1 | 1998 | 258 | 0.010 |
Why?
|
| Catalase | 1 | 1997 | 85 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 124 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1998 | 305 | 0.010 |
Why?
|
| Linear Models | 1 | 1998 | 521 | 0.010 |
Why?
|
| Drug Stability | 1 | 1994 | 71 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1994 | 45 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 14862 | 0.010 |
Why?
|
| Species Specificity | 1 | 1994 | 303 | 0.010 |
Why?
|
| Logistic Models | 1 | 1998 | 1420 | 0.010 |
Why?
|
| Biomarkers | 1 | 1999 | 1593 | 0.010 |
Why?
|
| Thionucleosides | 1 | 1989 | 2 | 0.010 |
Why?
|
| S-Adenosylmethionine | 1 | 1989 | 9 | 0.010 |
Why?
|
| Leukemia L1210 | 1 | 1989 | 14 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1989 | 100 | 0.010 |
Why?
|